Alexander Raths / shutterstock.com
The ‘promise doctrine’ has had, and will probably continue to have, a damaging impact on Canada’s investment portfolio, a report has said.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
promise doctrine, investment, research and development, Charles River Associates, patent, generics
